<DOC>
	<DOCNO>NCT00729963</DOCNO>
	<brief_summary>The primary objective study observe Sibutramine effective improving symptom sign sleep apnea obese patient . The secondary objective document effect Sibutramine heart rate variability 24-h arterial pressure value . We hypothesize sibutramine improve sleep disordered breathing , cardiac autonomic function systemic blood pressure obese patient obstructive sleep apnea ( OSA ) .</brief_summary>
	<brief_title>Sibutramine Versus Continuous Positive Airway Pressure ( CPAP ) Obstructive Sleep Apnea ( OSA ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Sibutramine</mesh_term>
	<criteria>Eligible participant nontreated OSA syndrome age 18 65 year , bodymass index ( BMI ) ≥ 30 kg/m2 ≥ 27 kg/m2 presence risk factor control systemic hypertension , type 2 diabetes , dyslipidemia and/or visceral obesity ( defined waist circumference ≥ 102 cm men ≥ 88 cm woman ) . Exclusion criterion uncontrolled systemic hypertension define blood pressure &gt; 145/90 mm Hg , previous pharmacological surgical treatment weight loss , already use CPAP severe diurnal hyper somnolence require immediate treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>